We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




AI Algorithm Combined With Blood Test Quickly and Accurately Diagnoses Heart Attacks in Women

By LabMedica International staff writers
Posted on 05 Sep 2022
Print article
Image: Artificial intelligence could help narrow heart attack gender gap (Photo courtesy of Unsplash)
Image: Artificial intelligence could help narrow heart attack gender gap (Photo courtesy of Unsplash)

Previous research has shown that women in the UK who have a heart attack receive poorer care than men at every stage. Women were 50% more likely to receive a wrong initial diagnosis, highlighting the need for innovations to help close the heart attack gender gap. Measuring the protein troponin in the blood is the current gold standard for diagnosing a heart attack. However, the levels of troponin released by the heart vary between men and women, with age and other health conditions. Current guidelines use the same threshold for all patients, meaning current tests are not as accurate as they could be. Now, an algorithm developed using artificial intelligence (AI) could help doctors to diagnose heart attacks in women more accurately and quicker than ever before.

Researchers at the University of Edinburgh (Edinburgh, Scotland) combined data from 10,038 people (48% women) who went to hospital with a suspected heart attack to develop an AI-based tool to help clinicians diagnose heart attacks more accurately. They then validated it on a further 3,035 people (31% women) outside of the UK. The tool, called CoDE-ACS, uses AI to combine routinely collected patient information when they arrive at hospital (including sex, age, observations, ECG findings and medical history) with the results from the troponin blood test. This then produces a score of 0 to 100.

The team found that CoDE-ACS was able to rule out a heart attack with 99.5% accuracy, confirming they were safe to go home. It also identified those who would benefit from staying in hospital for further tests, in whom the final diagnosis was a heart attack, with an accuracy of 83.7%. This compares to an accuracy of just 49.4% with current tests. Fewer than half of those identified for further testing using current approaches had a diagnosis of heart attack. The performance of the tool was consistent regardless of sex, age and pre-existing health conditions. Current tests mean that some patients’ troponin levels do not fit into the ‘rule in’ or ‘rule out’ thresholds, making clinical decisions more challenging. However, with a second troponin measurement, CoDE-ACS was able refine risk in the 29.5% of people who did not fit the simple ‘rule in’ or ‘rule out’ criteria allowing accurate determination if further action was needed.

“This is a huge step forward which promises to ensure everyone is on a level playing field when it comes to heart attack diagnosis and treatment,” said Professor James Leiper, our Associate Medical Director. “We know that women are more likely to receive a misdiagnosis, but by harnessing the power of AI, this team could provide one solution that helps to make that an issue of the past.”

“We’ve now embedded our algorithm into an easy-to-use mobile app to support doctors in guiding treatment decisions,” said Dimitrios Doudesis, data scientist at the BHF Centre for Cardiovascular Science, University of Edinburgh. “Whilst the troponin test takes 30 minutes to process, we take an array of other health information and add it into the app alongside the troponin measurement. This provides doctors with a precise and instantaneous score to confirm if they can reassure their patient that they haven’t had a heart attack and send them home, or if they require further tests.”

Related Links:
University of Edinburgh

New
Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Automated Blood Typing System
IH-500 NEXT
New
Laboratory Electric Thermostat
DNP-9025A
New
Hepato Fibrosis Assays
Hepato Fibrosis Assays

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more

Pathology

view channel
Image: The artificial intelligence models can personalize immune therapies in oncology patients (Photo courtesy of 123RF)

AI Tool Identifies Novel Genetic Signatures to Personalize Cancer Therapies

Lung cancer and bladder cancer are among the most commonly diagnosed cancers globally. Researchers have now developed artificial intelligence (AI) models designed to personalize immune therapies for oncology... Read more

Technology

view channel
Image: Schematic diagram of nanomaterial-based anti-epileptic drug concentration diagnostic technology (Photo courtesy of KRISS)

Nanomaterial-Based Diagnostic Technology Accurately Monitors Drug Therapy in Epilepsy Patients

Many patients with epilepsy take anti-epileptic drugs to control frequent seizures in their daily lives. To optimize treatment and avoid side effects from overdosing, it is crucial for patients to regularly... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.